Cingulate Inc. Announces Board Restructuring and New Chairman Appointment
CING sits 40% above its 52-week low of $3.2.
Summary
Cingulate Inc. is reducing its board size and appointing a new chairman, signaling a governance restructuring amidst ongoing financial challenges.
Key Events · Executive and Board Changes · CING
-
Board Size Reduction
Two Class II directors, Jeff Ervin and Jay Roberts, will not seek re-election when their terms expire at the 2026 Annual Meeting, leading to a reduction in the Board's size to five directors.
-
New Chairman Appointment
The Board intends to appoint a new chairman, indicating a leadership change at the top of the governance structure.
-
Director Re-appointment
Jeff Hargroves resigned as a Class I director and was immediately re-appointed as a Class II director to maintain the required class balance on the Board.
Analysis · CING · Life Sciences
Cingulate Inc. is restructuring its Board of Directors, reducing its size from seven to five members and appointing a new chairman. This governance shift occurs as the company navigates a 'going concern' warning and continues to raise capital, suggesting a strategic effort to streamline leadership and potentially improve oversight during a critical financial period.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 29.5% of the 1605 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CING was trading at $4.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.3M. The 52-week trading range was $3.20 to $11.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.